BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 17561976)

  • 41. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
    Mazzaferri EL; Robbins RJ; Spencer CA; Braverman LE; Pacini F; Wartofsky L; Haugen BR; Sherman SI; Cooper DS; Braunstein GD; Lee S; Davies TF; Arafah BM; Ladenson PW; Pinchera A
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1433-41. PubMed ID: 12679418
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
    Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
    Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Follow-up of differentiated thyroid cancer.
    Pacini F
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum thyroglobulin measurements in differentiated thyroid cancer.
    Girelli ME; De Vido D
    Biomed Pharmacother; 2000 Jul; 54(6):330-3. PubMed ID: 10989968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
    Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
    J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing?
    Díaz-Soto G; Puig-Domingo M; Martínez-Pino I; Martínez de Osaba MJ; Mora M; Rivera-Fillat F; Halperin I
    Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):348-52. PubMed ID: 21264807
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays?
    Rosario PW; Purisch S
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):338-42. PubMed ID: 17850379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative evaluation of two methods to assay thyroglobulin serum concentrations in patients with differentiated thyroid carcinomas.
    Ferrari L; Seregni E; Aliberti G; Martinetti A; Pallotti F; Villano C; Lucignani G; Bombardieri E
    Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):237-42. PubMed ID: 15499298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
    Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
    Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Significance of Low Levels of Thyroglobulin Autoantibodies Associated with Undetectable Thyroglobulin After Thyroidectomy for Differentiated Thyroid Carcinoma.
    Latrofa F; Ricci D; Sisti E; Piaggi P; Nencetti C; Marinò M; Vitti P
    Thyroid; 2016 Jun; 26(6):798-806. PubMed ID: 27020734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
    Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
    J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin.
    Westbury C; Vini L; Fisher C; Harmer C
    Thyroid; 2000 Feb; 10(2):171-6. PubMed ID: 10718555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
    Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
    Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
    Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
    Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.
    Pacini F; Lippi F
    J Endocrinol Invest; 1999; 22(11 Suppl):25-9. PubMed ID: 10727002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences in serum thyroglobulin measurements by 3 commercial immunoradiometric assay kits and laboratory standardization using Certified Reference Material 457 (CRM-457).
    Lee JI; Kim JY; Choi JY; Kim HK; Jang HW; Hur KY; Kim JH; Kim KW; Chung JH; Kim SW
    Head Neck; 2010 Sep; 32(9):1161-6. PubMed ID: 20029980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer.
    Piccardo A; Arecco F; Morbelli S; Bianchi P; Barbera F; Finessi M; Corvisieri S; Pestarino E; Foppiani L; Villavecchia G; Cabria M; Orlandi F
    J Endocrinol Invest; 2010 Feb; 33(2):83-7. PubMed ID: 19636213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.